




RealRate

PHARMACEUTICAL 2014

American BIO Medica CORP
Rank 153 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of American BIO Medica CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of American BIO Medica CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 56% points. The greatest weakness of American BIO Medica CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 182% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 55% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	3,739
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,357
Liabilities, Non-Current	147
Other Assets	137
Other Compr. Net Income	0
Other Expenses	7,356
Other Liabilities	124
Other Net Income	655
Other Revenues	8,894
Property and Equipment	1,090
Research and Development	645
Selling, General and Administrative Expense	2,336

Output Variable	Value in 1000 USD
Assets	4,966
Liabilities	3,628
Expenses	10,337
Revenues	8,894
Stockholders Equity	1,338
Net Income	-788
Comprehensive Net Income	-788
BaseVar	14,240
ECR before Limited Liability	50%
Economic Capital Ratio	188%